Physician profile
Sam Bruce Wu
NPI 1033503164
$8,625.94
in general payments reported to CMS, 2019-2025
31 companies · $2,668 in 2025
The $2,668 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $1,044 · 2023: $1,618 · 2024: $3,133 · 2025: $2,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,221 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,220.99 |
| Education | $197.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.61 | 2022-2025 | Skyrizi, Rinvoq, Humira |
| Leo Pharma INC. | $980.84 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $801.68 | 2021-2025 | Tremfya |
| Pfizer INC. | $795.34 | 2022-2025 | |
| Galderma Laboratories, L.P. | $567.38 | 2022-2025 | Aklief, Nemluvio, Epsolay |
| Sun Pharmaceutical Industries INC. | $557.26 | 2022-2025 | Ilumya, Winlevi |
| Genzyme Corporation | $554.44 | 2022-2025 | |
| Ucb, INC. | $546.11 | 2022-2025 | Bimzelx |
| Lilly USA, LLC | $444.74 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $353.16 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $313.52 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $311.77 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.69 | 2023-2025 | Spevigo, Cyltezo |
| Medimetriks Pharmaceuticals, INC. | $114.72 | 2023-2024 | Clindacin Etz, Neo-Synalar |
| Amgen INC. | $109.45 | 2023-2024 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $107.43 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $69.49 | 2024 | Zoryve |
| Ani Pharmaceuticals, INC. | $64.19 | 2023 | Veregen |
| Journey Medical Corporation | $55.62 | 2022-2025 | |
| Tempus Ai, INC | $47.98 | 2024 | |
| Novartis Pharmaceuticals Corporation | $46.49 | 2023-2024 | |
| Strata Skin Sciences, INC. | $35.97 | 2022-2024 | Xtrac |
| Almirall LLC | $35.65 | 2023-2024 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $32.62 | 2022 | |
| Integra Lifesciences Corporation | $32.19 | 2024 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Fresenius Kabi USA, LLC | $26.66 | 2024 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.50 | 2024 | Cabtreo |
| Organon LLC | $18.90 | 2025 | Vtama |
| Botanix Sb INC | $16.82 | 2025 | Sofdra |
| Mission Pharmacal Company | $15.03 | 2022 | |
| Revance Therapeutics, INC. | $14.69 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.